Dr. Marcia H. Ratner, Ph.D. - Department of Pharmacology and Experimental Therapeutics,Boston University School of Medicine - Project Manager

Dr. Marcia H. Ratner

Ph.D.

Department of Pharmacology and Experimental Therapeutics,Boston University School of Medicine

Project Manager

Boston, Massachusetts | United States

Main Specialties: Neurology

Additional Specialties: Toxicology, Neurology, Pharmacology

ORCID logohttps://orcid.org/0000-0002-5508-3267


Top Author

Dr. Marcia H. Ratner, Ph.D. - Department of Pharmacology and Experimental Therapeutics,Boston University School of Medicine - Project Manager

Dr. Marcia H. Ratner

Ph.D.

Introduction

I earned my bachelors degree in Psychology from Boston University, where I made the Dean's list and was a member of Psi Chi, the International Honor Society in Psychology. I went on to earn my Doctoral degree in Behavioral Neuroscience from the Boston University School of Medicine, where I trained in the Department of Neurology under the supervision of Drs. Robert G. Feldman MD Professor and Chair, Department of Neurology and Raymon Durso MD, Director, Neuropharmacology Laboratory, VA Healthcare System. I subsequently completed a three year National Institutes on Aging funded Post Doctoral Fellowship in the Biochemistry of Aging under the guidance of Dr. David H. Farb in the Department of Pharmacology and Experimental Therapeutics at the Boston University School of Medicine. My extensive training, first at the bedside in the Department of Neurology, and then at the bench in the Department of Pharmacology and Experimental Therapeutics at the BUSM has provided me with genuine translational research experience in clinical and basic neuroscience and neurotoxicology. I am currently using cutting edge in vivo electrophysiological techniques to study chemical-induced changes in neural network activity in an effort to identify novel therapeutics for age-related neurodegenerative diseases.

Primary Affiliation: Department of Pharmacology and Experimental Therapeutics,Boston University School of Medicine - Boston, Massachusetts , United States

Specialties:

Additional Specialties:

Research Interests:


View Dr. Marcia H. Ratner’s Resume / CV

Metrics

Number of Publications

15

Publications

Number of Profile Views

3379

Profile Views

Number of Article Reads

216

Reads

Number of PubMed Central Citations

182

PubMed Central Citations

Education

May 2007
Boston University School of Medicine
NIH/NIA Post Doctoral Fellowship
Jan 1996 - May 2004
Boston University School of Medicine
PhD
Sep 1992 - May 1995
Boston University
BA

Experience

Jul 2017
Board Eligible in Toxicology
Mar 2016
BU-CTSI Funding Opportunity Award
Award Recipient
May 2007
Boston University School of Medicine
Project Manager
Institutional Animal Care and Use Committee (IACUC) at Boston University School of Medicine
Board Member

Publications

15Publications

216Reads

182PubMed Central Citations

Is it Possible for Late-Onset Schizophrenia to Masquerade as Manganese Psychosis?

J Occup Environ Med 2018 04;60(4):e207-e209

View Article
April 2018
47 Reads
1.80 Impact Factor

Amyotrophic lateral sclerosis—A case report and mechanistic review of the association with toluene and other volatile organic compounds.

J Ind Med. 2017 Nov 10.

American Journal of Industrial Medicine

Unmasking of latent neurodegenerative disease has been reported following exposure to chemicals that share one or more mechanisms of action in common with those implicated in the specific disease. For example, unmasking of latent Parkinson's disease (PD) has been associated with exposure to anti-dopaminergic agents, while the progression of pre-existing mild cognitive impairment and unmasking of latent Alzheimer's disease has been associated with exposure to general anesthetic agents which promote Aβ protein aggregation. This literature review and clinical case report about a 45-year-old man with no family history of motor neuron disease who developed overt symptoms of a neuromuscular disorder in close temporal association with his unwitting occupational exposure to volatile organic compounds (VOCs) puts forth the hypothesis that exposure to VOCs such as toluene, which disrupt motor function and increase oxidative stress, can unmask latent ALS type neuromuscular disorder in susceptible individuals.

View Article
November 2017
38 Reads

Understanding of the role of manganese in parkinsonism and Parkinson disease.

Neurology 2017 01 28;88(4):338-339. Epub 2016 Dec 28.

From the Laboratory of Molecular Neurobiology (M.H.R.), Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, MA; and Department of Environmental Health Sciences (E.F.), School of Public Health, University at Albany, Rensselaer, NY.

View Article
January 2017
26 Reads
8.29 Impact Factor

Neurobehavioral Toxicology.

Ratner, M.H., Jabre, J.F. Neurobehavioral Toxicology. In Reference Module in Neuroscience and Biobehavioral Psychology, Elsevier, 2017. ISBN 9780128093245

Reference Module in Neuroscience and Biobehavioral Psychology,.

The field of neurobehavioral toxicology is the branch of toxicology dedicated to understanding the adverse effects of chemical and biological agents on the nervous system. Paracelsus, the Swiss German philosopher, physician credited as the founder of toxicology once said, “Poison is in everything, and there is no thing that is without poison. The dosage makes it either a poison or a remedy.” Unfortunately many chemicals intended to improve the quality of our lives also have the potential to cause acute and permanent changes in our behavior. This article reviews these behavioral manifestations in terms of the acute and persistent chemical induced changes in brain function and how behavioral testing is used in conjunction with clinical neurological, neurophysiological, and neuroimaging studies to make the differential diagnosis of toxic encephalopathy, toxic neuropathy and neurotoxicant-induced parkinsonism.

http://www.sciencedirect.com/science/article/pii/B9780128093245031175

View Article
October 2016
15 Reads

The Future Role of In vivo Electrophysiology in Preclinical Drug Discovery

Authors:
Marcia H Ratner

EC Pharmacol Toxicol 2016 Sept 2(2):108-109.

EC Pharmacology and Toxicology

Although a mainstay of preclinical drug discovery, the translational value of animal behavioral models of neurodegenerative diseases and psychiatric disorders remains controversial. Thus, there is an unmet need for better animal models. In vivo electrophysiology permits the measurement of drug-induced changes in neural network activity while providing the investigator with objective biomarkers of neurological function which can be used to increase the translational value of behavioral observations made with preclinical animal models. This powerful method, which can be used in freely behaving animals, typically employs microelectrode arrays, which in turn allow investigators to simultaneously record single unit activity and local field potentials (LFPs) from multiple cells in multiple brain regions. Recordings can also be made from specific brain regions implicated in disease. For example, drug-induced changes in both single unit activity and LFPs in the CA3 and CA1 subregions of the hippocampus are potential biomarkers of drug effects on spatial learning and memory function implicated in animal models of prodromal Alzheimer’s disease. This translational preclinical method is also well suited for target-based as well as repurposing studies.

View Article
September 2016
24 Reads

Combined administration of levetiracetam and valproic acid attenuates age-related hyperactivity of CA3 place cells, reduces place field area, and increases spatial information content in aged rat hippocampus.

Hippocampus 2015 Dec 14;25(12):1541-55. Epub 2015 Jul 14.

Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.

View Article
December 2015
26 Reads
8 PubMed Central Citations(source)
4.16 Impact Factor

Targeting the modulation of neural circuitry for the treatment of anxiety disorders.

Pharmacol Rev 2014 Oct;66(4):1002-32

Laboratory of Molecular Neurobiology, Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts.

View Article
October 2014
28 Reads
12 PubMed Central Citations(source)
17.10 Impact Factor

Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides.

Interdiscip Toxicol 2014 Sep 30;7(3):123-33. Epub 2014 Dec 30.

Department of Neurology, Boston University School of Medicine, Boston, USA.

View Article
September 2014
27 Reads
5 PubMed Central Citations(source)

The current state of serum biomarkers of hepatotoxicity.

Toxicology 2008 Mar 5;245(3):194-205. Epub 2007 Dec 5.

Safety Assessment, Merck Research Laboratories, West Point, PA, USA.

View Article
March 2008
29 Reads
151 PubMed Central Citations(source)
3.62 Impact Factor

Parkinson’s Disease. Pfeiffer RF, and Ebadi M, (Eds)

Ratner MH, Feldman RG. Parkinson’s Disease. Pfeiffer RF, and Ebadi M, (Eds). Chapter 6., Environmental Toxins and Parkinson’s Disease. CRC Press. Boca Raton. 2004; 51-62.

View Article
January 2004
16 Reads

Essentials of Metal Neurotoxicity: Mechanisms and Pathology.

1(3):619-653

Clinics in Occupational and Environmental Medicine

Metals are ubiquitous. Exposure to metals has been associated with producing acute and chronic effects on the human nervous system ranging from disabling neuropathies to life-threatening encephalopathies. Many metals produce constellations of symptoms that strongly resemble those of idiopathic neurodegenerative diseases. Metals have been hypothesized as an etiology of Parkinson's disease, Alzheimer's disease, ans amyotrophic lateral sclerosis (ALS). Understanding the mechanisms of action of metals commonly encountered in the workplace and environment is essential for clinicians interested in preventing and treating their neurotoxic effects. This article deals with four frequently encountered metals: arsenic, lead, manganese, and mercury.

View Article
August 2001
25 Reads

The pathogenesis of neurodegenerative disease: neurotoxic mechanisms of action and genetics.

Curr Opin Neurol 1999 Dec;12(6):725-31

Department of Neurology, School of Medicine, Boston University, 02118-2526, USA.

View Article
December 1999
19 Reads
1 PubMed Central Citation(source)
5.31 Impact Factor

Approach to Neurotoxicity Tort Cases.

17(2):267-281

Neurologic Clinics

This article provides the neurologist with simple methods that can be applied to all clinical neurologic evaluations, regardless of the future potential for litigation. This article defines the appropriate application and interpretation of conventional neurologic, neurophysiologic, neuropsychological, and biochemical diagnostic tests that are sensitive to neurotoxic exposures. This article also provides the neurologist with guidance in the preparation of clinical findings and tips on the recognition and use of supportive literature that is often required for admissibility of evidence at a deposition or testimony.

View Article
June 1999
24 Reads

Chronic toxic encephalopathy in a painter exposed to mixed solvents.

Environ Health Perspect 1999 May;107(5):417-22

Environmental and Occupational Neurology Program, Department of Neurology, Boston University School of Medicine, Boston, MA 02218, USA.

View Article
May 1999
14 Reads
5 PubMed Central Citations(source)
7.98 Impact Factor